Steve Wenglowsky

773 total citations
17 papers, 408 citations indexed

About

Steve Wenglowsky is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Steve Wenglowsky has authored 17 papers receiving a total of 408 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 7 papers in Oncology and 5 papers in Organic Chemistry. Recurrent topics in Steve Wenglowsky's work include Melanoma and MAPK Pathways (10 papers), Protein Kinase Regulation and GTPase Signaling (8 papers) and Cancer Mechanisms and Therapy (3 papers). Steve Wenglowsky is often cited by papers focused on Melanoma and MAPK Pathways (10 papers), Protein Kinase Regulation and GTPase Signaling (8 papers) and Cancer Mechanisms and Therapy (3 papers). Steve Wenglowsky collaborates with scholars based in United States, New Zealand and China. Steve Wenglowsky's co-authors include Jianming Bao, William D. Wulff, Yoshito Kishi, Jeffrey W. Johannes, Joachim Rudolph, Louis S. Hegedus, Susan L. Gloor, Li Ren, Ellen R. Laird and David Moreno‐Mateos and has published in prestigious journals such as Journal of the American Chemical Society, Cancer Research and International Journal of Pharmaceutics.

In The Last Decade

Steve Wenglowsky

17 papers receiving 395 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Steve Wenglowsky United States 13 277 188 70 48 43 17 408
Jonas Grina United States 12 203 0.7× 280 1.5× 75 1.1× 47 1.0× 54 1.3× 15 481
Jung-Mi Hah South Korea 15 324 1.2× 247 1.3× 39 0.6× 38 0.8× 42 1.0× 21 504
Hugh Zhu China 11 274 1.0× 333 1.8× 59 0.8× 39 0.8× 42 1.0× 16 551
Jiong Lan China 11 134 0.5× 202 1.1× 40 0.6× 44 0.9× 84 2.0× 35 339
Manolis A. Fousteris Greece 16 341 1.2× 273 1.5× 39 0.6× 21 0.4× 97 2.3× 40 590
J.K.Y. Wong United States 11 238 0.9× 272 1.4× 44 0.6× 32 0.7× 61 1.4× 28 498
Karine Malagu United Kingdom 9 135 0.5× 239 1.3× 49 0.7× 34 0.7× 33 0.8× 11 376
Shaun R. Selness United States 10 114 0.4× 206 1.1× 51 0.7× 25 0.5× 54 1.3× 12 359
Malini Ravi United States 10 231 0.8× 178 0.9× 77 1.1× 19 0.4× 74 1.7× 10 416
Anthony S. Prokopowicz United States 9 195 0.7× 174 0.9× 40 0.6× 55 1.1× 57 1.3× 10 352

Countries citing papers authored by Steve Wenglowsky

Since Specialization
Citations

This map shows the geographic impact of Steve Wenglowsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steve Wenglowsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steve Wenglowsky more than expected).

Fields of papers citing papers by Steve Wenglowsky

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steve Wenglowsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steve Wenglowsky. The network helps show where Steve Wenglowsky may publish in the future.

Co-authorship network of co-authors of Steve Wenglowsky

This figure shows the co-authorship network connecting the top 25 collaborators of Steve Wenglowsky. A scholar is included among the top collaborators of Steve Wenglowsky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steve Wenglowsky. Steve Wenglowsky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
2.
House, Nealia C., Jian Guo, Ruduan Wang, et al.. (2022). Abstract 2306: BLU-222, an investigational, potent, and selective CDK2 inhibitor, demonstrated robust antitumor activity in CCNE1-amplified ovarian cancer models. Cancer Research. 82(12_Supplement). 2306–2306. 8 indexed citations
3.
Wenglowsky, Steve, Li Ren, Jonas Grina, et al.. (2014). Highly potent and selective 3-N-methylquinazoline-4(3H)-one based inhibitors of B-RafV600E kinase. Bioorganic & Medicinal Chemistry Letters. 24(8). 1923–1927. 16 indexed citations
4.
Wenglowsky, Steve, Jonas Grina, Ellen R. Laird, et al.. (2013). Imidazo[4,5-b]pyridine inhibitors of B-Raf kinase. Bioorganic & Medicinal Chemistry Letters. 23(21). 5896–5899. 24 indexed citations
5.
Cui, Yong, Po‐Chang Chiang, Edna F. Choo, et al.. (2013). Systemic in vitro and in vivo evaluation for determining the feasibility of making an amorphous solid dispersion of a B-Raf (rapidly accelerated fibrosarcoma) inhibitor. International Journal of Pharmaceutics. 454(1). 241–248. 8 indexed citations
6.
Wenglowsky, Steve. (2013). Pyrazolo[3,4-b]pyridine kinase inhibitors: a patent review (2008 – present). Expert Opinion on Therapeutic Patents. 23(3). 281–298. 22 indexed citations
7.
Ren, Li, Kateri A. Ahrendt, Jonas Grina, et al.. (2012). The discovery of potent and selective pyridopyrimidin-7-one based inhibitors of B-RafV600E kinase. Bioorganic & Medicinal Chemistry Letters. 22(10). 3387–3391. 14 indexed citations
8.
Wenglowsky, Steve, David Moreno‐Mateos, Ellen R. Laird, et al.. (2012). Pyrazolopyridine inhibitors of B-RafV600E. Part 4: Rational design and kinase selectivity profile of cell potent type II inhibitors. Bioorganic & Medicinal Chemistry Letters. 22(19). 6237–6241. 27 indexed citations
9.
Choo, Edna F., Bruno Alicke, Jason Boggs, et al.. (2011). Preclinical assessment of novel BRAF inhibitors: integrating pharmacokinetic-pharmacodynamic modelling in the drug discovery process. Xenobiotica. 41(12). 1076–1087. 5 indexed citations
10.
Wenglowsky, Steve, David Moreno‐Mateos, Joachim Rudolph, et al.. (2011). Pyrazolopyridine inhibitors of B-RafV600E. Part 3: An increase in aqueous solubility via the disruption of crystal packing. Bioorganic & Medicinal Chemistry Letters. 22(2). 912–915. 34 indexed citations
11.
Wenglowsky, Steve, Kateri A. Ahrendt, Bainian Feng, et al.. (2011). Pyrazolopyridine inhibitors of B-RafV600E. Part 2: Structure–activity relationships. Bioorganic & Medicinal Chemistry Letters. 21(18). 5533–5537. 50 indexed citations
12.
Ren, Li, Ellen R. Laird, Steve Wenglowsky, et al.. (2010). The Discovery of furo[2,3-c]pyridine-based indanone oximes as potent and selective B-Raf inhibitors. Bioorganic & Medicinal Chemistry Letters. 21(4). 1248–1252. 22 indexed citations
13.
Ren, Li, Steve Wenglowsky, Stephen T. Schlachter, et al.. (2010). Non-oxime inhibitors of B-RafV600E kinase. Bioorganic & Medicinal Chemistry Letters. 21(4). 1243–1247. 26 indexed citations
14.
Johannes, Jeffrey W., Steve Wenglowsky, & Yoshito Kishi. (2005). Biomimetic Macrocycle-Forming Diels−Alder Reaction of an Iminium Dienophile:  Synthetic Studies Directed Toward Gymnodimine. Organic Letters. 7(18). 3997–4000. 42 indexed citations
15.
Wenglowsky, Steve & Louis S. Hegedus. (1998). An Asymmetric Synthesis of Optically Pure α,α-Disubstituted Amino Aldehydes, α,α-Disubstituted Amino Acids, and Sterically Demanding Dipeptides. Journal of the American Chemical Society. 120(48). 12468–12473. 25 indexed citations
16.
Bao, Jianming, et al.. (1994). Three-Component Intramolecular Two-Alkyne Annulations of Fischer Carbene Complexes: New Strategies for Steroid Synthesis. Journal of the American Chemical Society. 116(17). 7616–7630. 50 indexed citations
17.
Bao, Jianming, et al.. (1991). Tandem Diels-Alder/double intramolecular two-alkyne annulations of Fischer carbene complexes: a one-pot construction of all four rings of the steroid ring system. Journal of the American Chemical Society. 113(26). 9873–9875. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jonas Grina Breakdown of academic impact, for papers by Jung-Mi Hah Breakdown of academic impact, for papers by Hugh Zhu Breakdown of academic impact, for papers by Jiong Lan Breakdown of academic impact, for papers by Manolis A. Fousteris Breakdown of academic impact, for papers by J.K.Y. Wong Breakdown of academic impact, for papers by Karine Malagu Breakdown of academic impact, for papers by Shaun R. Selness Breakdown of academic impact, for papers by Malini Ravi Breakdown of academic impact, for papers by Anthony S. Prokopowicz
Rankless by CCL
2026